CanSino Biologics Initiates Phase 1 Study of Pediatric Combination Vaccine

Cansino Biologics Inc. (688185.SH): DTcP-Hib-MCV4 Combined Vaccine Initiates Phase I Clinical Trial and Completes First Subject Enrollment

Southbound Capital Flow Data (T+2) for Dec 8

CanSino Biologics Inc. Files Board of Directors List to HKEX

Cansino's "Loss Cover-Up": Dividend Prospects Amid Lingering Operational Concerns

CanSino Biologics Launches Phase I Trial for Inhaled TB Booster in Indonesia

Cansino Biologics Inc. (688185.SH) Initiates Phase I Clinical Trial for Inhaled TB Booster Vaccine in Indonesia, Completes First Subject Enrollment

CanSino Biologics Signs Licensing Agreement With PanRu Biotech for Three-Component LNP Delivery System

CanSino Biologics' Profit Soars 842% in Q3; Shares Gain 4%

BRIEF-CanSino Biologics Q3 Net Profit Up 842.0% Y/Y

CanSino Biologics Q3 Net Profit up 842.0% Y/Y

CanSino Biologics Inc. Convenes Annual Scientific Advisory Board Meeting to Discuss Vaccine Innovation and Global Health Strategy

Cansino Biologics' Mid-Year Results Mask Underlying Concerns as 90% of Revenue Relies on Single Vaccine

CanSino Biologics Proposes New 2025 H Share Option Scheme, Pending Shareholder Approval

CanSino Biologics Announces Domestic Launch of iPneucia® and International Shipment of Menhycia®

Cansino Biologics Inc. (688185.SH) Plans to Launch A-Share Restricted Stock Incentive Plan for 2.58 Million Shares

CanSino Biologics Narrows Loss in H1 as Revenue Jumps 31%

CanSino Biologics H1 Revenue RMB 374.1 Million

Cansino Biologics Inc. (688185.SH) Reports First-Half Results with Net Loss of 13.49 Million Yuan, Narrowing Year-over-Year

CanSino Biologics H1 Net Loss 13.5 Mln Yuan